Kommentar zu „Rucaparib verlängert progressionsfreies Überleben bei metastasiertem Prostatakarzinom“

• Literatur

• 1 De Bono J. et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 2020; 382: 2091-2102
• 2 Hussain M. et al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer N Engl. J Med 2020; 383: 2345-2357
• 3 Bryce A. et al. Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy. Journal of Clinical Oncology 2023; 41 (Suppl. 06) 18-18